The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksIntercede Regulatory News (IGP)

Share Price Information for Intercede (IGP)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 104.00
Bid: 102.00
Ask: 106.00
Change: -1.50 (-1.42%)
Spread: 4.00 (3.922%)
Open: 105.50
High: 105.50
Low: 104.00
Prev. Close: 105.50
IGP Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Half Yearly Report

3 Nov 2015 07:00

RNS Number : 2902E
Intercede Group PLC
03 November 2015
 

 

 

 

3 November 2015

 

INTERCEDE GROUP plc

('Intercede', the 'Company' or the 'Group')

 

Interim Results for the Six Months Ended 30 September 2015

 

 

Intercede, the software and service company specialising in identity, credential management and secure mobility, today announces its interim results for the six months ended 30 September 2015.

 

Highlights

· Revenues of £5.5m (2014: £4.0m), an increase of 37%.

 

· Operating expenses increased to £5.7m (2014: £4.9m), as a result of continuing investment in infrastructure, technology development and sales capacity.

 

· Headcount increased to 125 at 30 September 2015 (30 September 2014: 116).

 

· Operating loss of £0.4m (2014: £1.1m).

 

· Profit for the period of £0.5m (2014: loss of £0.7m).

 

· Basic earnings per share 1.0p (2014: basic loss per share 1.4p).

 

· Cash balances of £5.8m remain strong at 30 September 2015 (30 September 2014: £6.3m).

 

· Four new contracts signed during period, which will all contribute to revenues during the current financial year and beyond:

 

Enterprise-wide contract with one of the largest US healthcare corporations.

 

Mobile Derived Credential solution sold to a major US Federal Agency.

 

New agreement with a US West Coast bank.

 

First sale following the announcement of the Partner Agreement with Citrix on 13 May 2015.

 

 

Richard Parris, Chairman & Chief Executive of Intercede, said:

 

"We continue to execute our strategy of attacking multiple markets within the broader spectrum of identity and credential management. The more mature market is where our MyID product has entrenched itself as the industry standard, based on a high margin and strongly cash generative business model. This in turn provides the financial stability to invest in the second strand of our strategy, which is to use our technical knowledge and industry network to exploit newer opportunities based on the convergence of mobile data, cybersecurity and the Internet of Things. While we must be mindful of the fact that because they are new, the timing of the conversion of these opportunities into committed orders is harder to predict, we are increasingly confident that the success we have enjoyed in delivering the first part of our strategy will be replicated."

 

ENQUIRIES

 

Intercede Group plc Tel. +44 (0)1455 558 111

Richard Parris, Chairman & Chief Executive

Andrew Walker, Finance Director

 

FinnCap Tel. +44 (0)20 7220 0500

Stuart Andrews, Corporate Finance

Joanna Weaving, Corporate Broking

 

Bell Pottinger Tel. +44 (0)7802 442486

Archie Berens

 

 

About Intercede

Intercede is a software and service company specialising in identity, credential management and secure mobility. Its solutions create a foundation of trust between connected people, devices and apps and combine expertise with innovation to provide world-class cybersecurity.

Intercede has been delivering solutions to high profile customers, from the US and UK governments to some of the world's largest corporations, telecommunications providers and information technology firms, for over 20 years.

Intercede's MyID software is an identity and credential management system that enables organisations to create and assign trusted digital identities to employees, citizens and machines and in turn allows secure access to services, facilities, information and networks. MyID adheres to international standards, while remaining simple enough to be deployed onto consumer devices such as smartphones, tablets and other devices in the Internet of Things.

In 2015 Intercede launched MyTAM; enabling trusted applications to be loaded into a mobile device's Trusted Execution Environment (TEE), providing hardware-level security for Android apps. The cloud-based service provides a cost-effective and convenient way for developers and corporations to protect their apps and users' sensitive data.

For more information visit: www.intercede.com

 

INTERCEDE GROUP plc

('Intercede', 'the Company' or 'the Group')

 

Interim Results for the Six Months Ended 30 September 2015

 

Chairman's Statement

 

Introduction

 

Intercede has enjoyed a successful first half of the current financial year. We have grown revenues and maintained a strong financial position, whilst also making good progress in the newer markets where we believe there is significant scope for our latest suite of products to secure a leading position.

 

The Group's short to medium term financial target is to deliver accelerated revenue growth by investing in people and resources to take advantage of the opportunities provided by the impact of smart phones and global cybersecurity concerns. This strategic investment has been funded organically to date.

 

Financial Results

 

As previously stated, Intercede has achieved strong revenue growth during the first half of the financial year. This is in line with market expectations and reflects continued progress with existing customers and a number of new contract wins.

 

Revenues in the period totaled £5,547,000, a 37% increase compared to £4,045,000 in the corresponding period last year. Existing and new products have gained traction in target markets with significant revenues expected in future periods.

 

Planned investment in additional resources as outlined above has resulted in a 16% increase in operating expenses from £4,868,000 to £5,670,000. The combined effect of increased revenues and planned investment has resulted in a substantial reduction in operating losses from £1,119,000 to £447,000.

 

Staff costs continue to represent the main area of expense, representing 78% of total operating costs (2014: 77%). Intercede had 125 employees and contractors as at 30 September 2015 (30 September 2014: 116). The average number of employees and contractors during the period increased from 110 to 121 year on year.

 

A £912,000 taxation credit for the period (2014: £383,000 taxation credit) primarily reflects cash received following the 2015 Research & Development ("R&D") claim as a result of the investment activities outlined above. The Group is a beneficiary of the UK Government's efforts to encourage innovation by allowing 125% of qualifying R&D expenditure to be offset against taxable profits and allowing 14.5% (2014: 11.0%) of the lower of R&D losses or taxable losses to be paid as tax credits.

 

A profit for the period of £480,000 (2014: loss of £705,000) resulted in a basic earnings per share of 1.0p and a fully diluted earnings per share of 0.9p (2014: basic and fully diluted loss per share 1.4p).

 

The Group has no debt and continues to fund its growth through existing cash resources. Cash balances as at 30 September 2015 totaled £5,767,000 compared to £5,895,000 as at 31 March 2015 and £6,301,000 as at 30 September 2014.

 

Operational Highlights

 

This has been a very busy period in terms of product development and customer engagement. The following additional contract wins were added to the order book during the period, all of which will contribute to revenues in the current financial year and beyond:

 

· Enterprise-wide contract with one of the largest US healthcare corporations.

 

· Mobile Derived Credential solution sold to a major US Federal Agency.

 

· New agreement with a US West Coast bank.

 

· First sale following the announcement of the Partner Agreement with Citrix on 13 May 2015.

 

Strategy and Outlook

 

Intercede's strategy is to grow its digital trust service and software business from a core of existing high value reference customers to a much broader range of industry sectors and customer size.

 

Intercede plans to achieve this by continuing to generate revenues in its historically strong markets and to reinvest in the significantly higher growth opportunity that is anticipated in the Cloud-enabled, application service centric, mobile and Internet of Things markets. For example, in the next few weeks Intercede will announce details of a new business unit to be headquartered in California. This new team will focus on creating disruptive opportunities by exploiting the value of digital trust in both the consumer and general enterprise markets.

 

Intercede has already developed much of the required core technology, such as the MyID and MyTAM platforms. The strategic focus is now moving to packaging Intercede's portfolio of IP assets into new combinations to provide innovative solutions to some of the most intractable challenges of the digital economy. In doing so there is the potential for a step change in revenue and strategic value. To deliver this Intercede has streamlined its development processes, enlarged its sales team, expanded its geographical footprint and invested in new business development functions.

 

We believe the upside of success is huge. For example, trusted applications on mobile devices will increase convenience, privacy and security for everyday consumer and business applications and, by 2020, the Internet of Things market is estimated to be in excess of 50 billion devices with each 'thing' needing to validate the trustworthiness of its peers across a network. Each point of trust is an opportunity for Intercede to provide an enabling service.

 

Our expectations are for accelerating year on year growth. In the longer term it has become clear that Intercede is exceptionally well placed to capitalise on the market for digital trust services.

 

 

Richard Parris

Chairman & Chief Executive

3 November 2015

Consolidated Statement of Comprehensive Income

For the period ended 30 September 2015

6 months ended

30 September 2015

6 months ended

30 September 2014

Year ended 31 March

2015

£'000

£'000

£'000

Continuing operations

Revenue

5,547

4,045

8,819

Cost of sales

(324)

(296)

(344)

__________

__________

__________

Gross profit

5,223

3,749

8,475

Operating expenses

(5,670)

(4,868)

(10,215)

__________

__________

__________

Operating loss

(447)

(1,119)

(1,740)

Finance income

15

31

68

__________

__________

__________

Loss before tax

(432)

(1,088)

(1,672)

Taxation

912

383

363

__________

__________

__________

Profit/(loss) for the period

480

(705)

(1,309)

__________

__________

__________

Total comprehensive income/(expense) attributable to owners of the parent company

480

(705)

(1,309)

__________

__________

__________

Earnings/(loss) per share (pence)

- basic

1.0p

(1.4)p

(2.7)p

- diluted

0.9p

(1.4)p

(2.7)p

__________

__________

__________

Consolidated Balance Sheet

As at 30 September 2015

As at

 30 September 2015

As at

30 September 2014

As at

31 March

2015

£'000

£'000

£'000

Non-current assets

Property, plant and equipment

835

786

853

__________

__________

__________

Current assets

Trade and other receivables

1,812

1,744

1,074

Cash and cash equivalents

5,767

6,301

5,895

__________

__________

__________

7,579

8,045

6,969

__________

__________

__________

Total assets

8,414

8,831

7,822

__________

__________

__________

Equity

Share capital

487

487

487

Share premium account

232

232

232

Other reserves

1,508

1,508

1,508

Retained earnings

2,453

3,010

2,257

__________

__________

__________

Total equity attributable to owners of the parent company

4,680

5,237

4,484

__________

__________

__________

Non-current liabilities

Deferred revenue

210

48

229

__________

__________

__________

Current liabilities

Trade and other payables

1,109

1,396

1,126

Deferred revenue

2,415

2,150

1,983

__________

__________

__________

3,524

3,546

3,109

__________

__________

__________

Total liabilities

3,734

3,594

3,338

__________

__________

__________

Total equity and liabilities

8,414

8,831

7,822

__________

__________

__________

 

Consolidated Statement of Changes in Equity

For the period ended 30 September 2015

Share capital

Share premium

Other reserves

Retained earnings

Total

£'000

£'000

£'000

£'000

£'000

At 1 April 2015

487

232

1,508

2,257

4,484

Purchase of own shares

-

-

-

(488)

(488)

Employee share option plan charge

-

-

-

57

57

Employee share incentive plan charge

-

-

-

147

147

Profit for the period and total comprehensive income

-

-

-

480

480

________

________

________

________

_______

At 30 September 2015

487

232

1,508

2,453

4,680

________

________

________

___________

_______

At 1 April 2014

487

232

1,508

3,972

6,199

Purchase of own shares

-

-

-

(379)

(379)

Employee share option plan charge

-

-

-

62

62

Employee share incentive plan charge

-

-

-

60

60

Loss for the period and total comprehensive expense

-

-

-

(705)

(705)

________

________

________

________

_______

At 30 September 2014

487

232

1,508

3,010

5,237

________

________

________

___________

_______

At 1 April 2014

487

232

1,508

3,972

6,199

Purchase of own shares

-

-

-

(688)

(688)

Employee share option plan charge

-

-

-

118

118

Employee share incentive plan charge

-

-

-

164

164

Loss for the year and total comprehensive expense

-

-

-

(1,309)

(1,309)

________

________

________

________

_______

At 31 March 2015

487

232

1,508

2,257

4,484

________

________

________

___________

_______

 

Consolidated Cash Flow Statement

For the period ended 30 September 2015

6 months ended 30 September 2015

6 months ended 30 September 2014

Year ended

31 March 2015

£'000

£'000

£'000

Cash flows from operating activities

Operating loss

(447)

(1,119)

(1,740)

Depreciation

89

72

153

Employee share option plan charge

57

62

118

Employee share incentive plan charge

147

60

164

(Increase)/decrease in trade and other receivables

(742)

41

709

(Decrease) in trade and other payables

(17)

(323)

(593)

Increase in deferred revenue

413

327

341

Interest received

19

31

70

__________

__________

__________

Cash used in operations

(481)

(849)

(778)

Taxation

912

383

363

__________

__________

__________

Net cash generated from/(used in) operating activities

431

(466)

(415)

__________

__________

__________

Investing activities

Purchases of property, plant and equipment

(71)

(101)

(249)

__________

__________

__________

Cash used in investing activities

(71)

(101)

(249)

__________

__________

__________

Financing activities

Purchase of own shares

(488)

(379)

(688)

__________

__________

__________

Cash used in financing activities

(488)

(379)

(688)

__________

__________

__________

Net decrease in cash and cash equivalents

(128)

(946)

(1,352)

Cash and cash equivalents at the beginning of the period

5,895

7,247

7,247

__________

__________

__________

Cash and cash equivalents at the end of the period

5,767

6,301

5,895

__________

__________

__________

Notes to the Consolidated Accounts

For the period ended 30 September 2015

 

1 Preparation of the interim financial statements

These interim financial statements have been prepared under IFRS as adopted by the European Union and on the basis of the accounting policies set out in the Group's Annual Report for the year ended 31 March 2015.

 

The Group is not required to apply IAS 34 Interim Financial Reporting at this time.

These interim financial statements have not been audited and do not constitute statutory accounts as defined in Section 434 of the Companies Act 2006. Statutory accounts for the year ended 31 March 2015 have been delivered to the Registrar of Companies. The Auditors' Report on those accounts was unqualified and did not contain any statement under Section 498 (2) or (3) of the Companies Act 2006.

 

The Interim Report will be mailed to shareholders within the next few weeks and copies will be available on the website (www.intercede.com) and at the registered office: Intercede Group plc, Lutterworth Hall, St Mary's Road, Lutterworth, Leicestershire, LE17 4PS.

 

 

2 Revenue

All of the Group's revenue, operating profits and net assets originate from operations in the UK. The Directors consider that the activities of the Group constitute a single business segment.

 

The split of revenue by geographical destination of the end customer can be analysed as follows:

 

 

6 months ended

30 September 2015

6 months ended 30 September 2014

Year ended 31 March 2015

£'000

£'000

£'000

UK

313

746

1,301

Rest of Europe

570

815

1,848

North America

4,410

1,628

4,493

Rest of World

254

856

1,177

__________

__________

__________

5,547

4,045

8,819

__________

__________

__________

 

 

3 Taxation

Taxation represents the net effect of amounts receivable from HMRC in respect of R&D claims and US corporation tax payable.

 

 

 

 

 

 

 

 

 

4 Earnings/(loss) per share

The calculations of the earnings/(loss) per ordinary share are based on the profit/(loss) for the period and the weighted average number of ordinary shares in issue during each period. The basic and diluted loss per share are the same as potential dilution cannot be applied to a loss making period.

 

 

6 months ended

30 September 2015

6 months ended

30 September 2014

Year ended 31 March 2015

£'000

£'000

£'000

Profit/(loss) for the period

480

(705)

(1,309)

__________

__________

__________

Number

Number

Number

Weighted average number of shares

- basic

48,426,005

48,571,005

48,526,457

- diluted

50,517,373

48,571,005

48,526,457

__________

__________

__________

Pence

Pence

Pence

Earnings/(loss) per share

- basic

1.0p

(1.4)p

(2.7)p

- diluted

0.9p

(1.4)p

(2.7)p

__________

__________

__________

 

The weighted average number of shares used in the calculation of basic and diluted earnings per share for each period were calculated as follows:

6 months ended

30 September 2015

6 months ended

30 September 2014

Year ended 31 March 2015

Number

Number

Number

Issued ordinary shares at start of period

48,735,005

48,735,005

48,735,005

Effect of purchase of treasury shares

(309,000)

(164,000)

(208,548)

__________

__________

__________

Weighted average number of shares

- basic

48,426,005

48,571,005

48,526,457

__________

__________

__________

 

Add back effect of purchase of treasury shares

309,000

N/A

N/A

Effect of share options in issue

2,016,683

N/A

N/A

__________

__________

__________

Weighted average number of shares

- diluted

50,751,688

48,571,005

48,526,457

__________

__________

__________

 

5 Dividend

The Directors do not recommend the payment of a dividend.

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
IR ZMMGMNZVGKZM
Date   Source Headline
26th Apr 202410:02 amRNSShare Incentive Scheme
23rd Apr 20247:00 amRNSCapital Markets Day
8th Apr 20247:00 amRNSTrading Update
2nd Apr 20247:00 amRNSContract and Subscription Renewals
25th Mar 20243:38 pmRNSHolding(s) in Company
25th Mar 20243:35 pmRNSHolding(s) in Company
22nd Mar 20247:00 amRNSNew Orders and Trading Update
21st Mar 20247:00 amRNSNew Product Announcement: Launch of MyID MFA v5
6th Feb 20247:00 amRNSDirector/PDMR Shareholding
29th Jan 20247:00 amRNSNew Orders
18th Jan 20249:55 amRNSDirector/PDMR Shareholding
3rd Jan 20247:00 amRNSMajor New Contract Win
7th Dec 20237:00 amRNSUpdate on Major New Contract Win
5th Dec 202312:30 pmRNSMajor New Contract with Large US Federal Agency
22nd Nov 20237:00 amRNSDirector/PDMR Shareholding
21st Nov 20237:01 amRNSNew Contract and Renewal Orders
21st Nov 20237:00 amRNSHalf-year Report
7th Nov 20237:00 amRNSContract and Renewals Orders
25th Oct 20234:44 pmRNSDirector/PDMR Shareholding
24th Oct 20237:00 amRNSNotice of Interim Results & Investor Presentation
20th Oct 20237:03 amRNSAppointment of Non-Executive Director
11th Oct 20237:00 amRNSDirector/PDMR Shareholding
10th Oct 20237:00 amRNSTrading Update
21st Sep 20231:31 pmRNSResult of AGM
4th Sep 20237:00 amRNSContract and Renewals Orders
30th Aug 20237:10 amRNSNotice of AGM and Publication of Annual Report
20th Jun 20237:01 amRNSBoard Changes
20th Jun 20237:00 amRNSFinal Results
12th Jun 20237:00 amRNSNotice of Results & Investor Presentation
27th Apr 20237:00 amRNSShare Incentive Plan
17th Apr 20237:00 amRNSTrading Update
3rd Apr 20237:00 amRNSContract wins/renewals
3rd Feb 202310:46 amRNSDirector/PDMR Shareholding
31st Jan 20237:00 amRNSChange of Auditors
23rd Jan 20234:40 pmRNSSecond Price Monitoring Extn
23rd Jan 20234:35 pmRNSPrice Monitoring Extension
23rd Jan 20232:05 pmRNSSecond Price Monitoring Extn
23rd Jan 20232:00 pmRNSPrice Monitoring Extension
23rd Jan 20237:00 amRNSTrading Update
11th Jan 20232:30 pmRNSDirector/PDMR Shareholding
2nd Dec 20228:45 amRNSDirector/PDMR Shareholding
22nd Nov 20227:00 amRNSHalf-year Report
11th Nov 20227:00 amRNSNotice of Interim Results & Investor Presentation
13th Oct 202210:30 amRNSDirector/PDMR Shareholding
11th Oct 20221:00 pmRNSDirector/PDMR Shareholding
10th Oct 20228:00 amRNSLong Term Incentive Plan
10th Oct 20227:01 amRNSAcquisition of Authlogics Ltd
10th Oct 20227:00 amRNSTrading Update
28th Sep 202212:22 pmRNSResult of AGM
15th Sep 20227:00 amRNSDirector/PDMR Shareholding and Issue of Equity

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.